The Lipodystrophy (Lipoatrophy) drugs in development market research report provides comprehensive information on the therapeutics under development for Lipodystrophy (Lipoatrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Lipodystrophy (Lipoatrophy). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Lipodystrophy (Lipoatrophy) and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Lipodystrophy (Lipoatrophy) by nine companies/universities/institutes. The top development phase for Lipodystrophy (Lipoatrophy) is preclinical with four drugs in that stage. The Lipodystrophy (Lipoatrophy) pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Lipodystrophy (Lipoatrophy) pipeline products market are: Ionis Pharmaceuticals, Chiesi Farmaceutici and Regeneron Pharmaceuticals.
The key targets in the Lipodystrophy (Lipoatrophy) pipeline products market include Leptin Receptor, Leptin, and Fibroblast Growth Factor 21.
The key mechanisms of action in the Lipodystrophy (Lipoatrophy) pipeline product include Leptin Receptor Agonist with two drugs in Phase III. The Lipodystrophy (Lipoatrophy) pipeline products include four routes of administration with the top ROA being Oral and six key molecule types in the Lipodystrophy (Lipoatrophy) pipeline products market including Gene Therapy, and Monoclonal Antibody.
Lipodystrophy (Lipoatrophy) overview
Lipodystrophy syndromes comprise a heterogeneous group of disorders characterized by either generalized or partial lack of adipose tissue depending on the type of lipodystrophy. Lipodystrophy has been classified as congenital or acquired. Lipodystrophy syndromes usually manifest with several metabolic abnormalities associated with severe insulin resistance that include diabetes mellitus, hypertriglyceridemia, and hepatic steatosis, which can progress to steatohepatitis.
For a complete picture of Lipodystrophy (Lipoatrophy)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
